Want to see HK:1099 full AI Analyst Report?
Top Page
Sinopharm Group Co
(1099)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$18.50
▲(15.99% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily driven by mixed financial performance (stable earnings and cash generation but recent revenue decline, margin compression, and rising leverage) balanced by attractive valuation (low P/E and strong dividend yield). Technicals are neutral with mild positive momentum, but longer-term moving averages still signal a softer trend.
Positive Factors
Distribution Scale and Network
Sinopharm’s nationwide distribution infrastructure and healthcare-provider coverage support purchasing scale, recurring institutional demand, and operational barriers for smaller competitors. These capabilities can remain strategically valuable across the multi-month outlook.
Negative Factors
Recent Revenue Contraction
Recent revenue contraction follows stronger growth in 2021–2023 and suggests weaker demand, pricing, or volume across the distribution platform. Sustained low growth would limit operating leverage and reduce the capacity to expand earnings over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Distribution Scale and Network
Sinopharm’s nationwide distribution infrastructure and healthcare-provider coverage support purchasing scale, recurring institutional demand, and operational barriers for smaller competitors. These capabilities can remain strategically valuable across the multi-month outlook.
Read all positive factors
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$49.40B
Dividend Yield4.93%
Average Volume (3M)4.70M
Price to Earnings (P/E)6.1
Beta (1Y)0.77
Revenue Growth2.78%
EPS Growth7.71%
CountryHK
Employees90,447
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)2.29
Shares Outstanding1,341,810,800
10 Day Avg. Volume6,219,269
30 Day Avg. Volume4,701,404
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)0.65
Price to Sales (P/S)0.09
P/FCF Ratio4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$21.80Price Target Upside36.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.3
Revenue Forecast (FY)HK$580.17B
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are ...
How the Company Makes Money
Sinopharm primarily makes money by distributing pharmaceuticals and healthcare products at scale and earning a margin between its procurement cost and the selling price to downstream customers. Its core revenue streams typically include: (1) Pharm...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
60
Neutral
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 575.17B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 41.67B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 19.26B | 20.17B | 26.90B | 26.25B | 24.68B |
| Net Income | 7.16B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | |||||
| Total Assets | 390.53B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 61.59B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 108.63B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 256.31B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 83.99B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | |||||
| Free Cash Flow | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Negative
15.95
Price Trends
16.74
Negative
16.86
Negative
18.23
Negative
Market Momentum
-0.33
Positive
45.58
Neutral
61.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1099, the sentiment is Negative. The current price of 15.95 is below the 20-day moving average (MA) of 16.17, below the 50-day MA of 16.74, and below the 200-day MA of 18.23, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 45.58 is Neutral, neither overbought nor oversold. The STOCH value of 61.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1099.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.17B | 13.03 | 7.00% | 4.15% | 6.47% | 8.10% | |
70 Outperform | HK$594.00M | 10.95 | 7.70% | 6.25% | 14.28% | 0.81% | |
65 Neutral | HK$49.40B | 6.10 | 8.33% | 4.93% | 2.78% | 7.71% | |
55 Neutral | HK$64.51B | 12.84 | 6.21% | 4.65% | 8.02% | -17.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$416.14M | -6.62 | -273.18% | ― | 5.52% | 56.54% | |
37 Underperform | HK$891.82M | -9.64 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:1099
Sinopharm Group Co
15.70
-2.16
-12.09%
HK:0673
China Health Group
0.31
-0.15
-32.61%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.51
-0.07
-0.64%
HK:1931
IVD Medical Holding Limited
0.51
-9.89
-95.10%
HK:2192
Medlive Technology Co., Ltd.
7.01
-6.29
-47.31%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
-0.18
-3.15%
Sinopharm Group Co Corporate Events
Sinopharm Subsidiary Posts Higher Revenue but Lower Profits in First-Half 2026
Aug 19, 2026
Sinopharm Group has released unaudited interim figures for China National Medicines, showing revenue of RMB 26.73 billion for the six months to 30 June 2026, up 4.27% year on year, while net profit attributable to shareholders fell 7.25% to RMB 87...
Sinopharm Subsidiary CNMDC Posts Weak Margins Amid Asset Growth
Aug 19, 2026
Sinopharm revealed unaudited interim financial figures for subsidiary China National Medical Device Co., Ltd. for the six months ended 30 June 2026, showing revenue of RMB 36.49 billion, up 0.36% year on year, and total assets rising 7.73% to RMB ...
Sinopharm Reshapes Key Board Committees to Bolster Governance
Aug 18, 2026
Sinopharm Group Co. Ltd. has reshaped the composition of several key board committees, appointing executive director Yang Binghua to the strategy and investment committee and adding non-executive directors Zu Jing and Wen Deyong to the audit commi...
Sinopharm Revamps Board Structure and Committee Roles
Aug 18, 2026
Sinopharm Group has updated the composition of its board of directors, listing non-executive, executive and independent non-executive members, with Jin Bin serving as chairman and Lian Wanyong as president. The announcement underscores a diversifi...
Sinopharm Accord Posts Lower First-Half Profit Despite Stable Revenue and Strong Equity Base
Aug 17, 2026
Sinopharm Accord, a Shenzhen-listed subsidiary of Sinopharm Group, reported broadly stable revenue but weaker profitability for the six months ended 30 June 2026, with total revenue slipping 1.44% year on year to RMB 36.27 billion. Net profit attr...
Sinopharm Board Sets August Meeting to Approve Interim Results
Aug 7, 2026
Sinopharm Group Co. Ltd. has announced that its board of directors will convene on Friday, 21 August 2026, to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will cover interim performance of the...
Sinopharm Sets Final 2025 Dividend and Clarifies Withholding Tax for H-Share Investors
Jun 18, 2026
Sinopharm Group has proposed a final ordinary cash dividend of RMB 0.69 per share for the financial year ended 31 December 2025, equivalent to HKD 0.79 per share based on an exchange rate of RMB 1 to HKD 1.15, with shareholder approval obtained on...
Sinopharm Shareholders Approve 2025 Results and Final Dividend at AGM
Jun 18, 2026
Sinopharm Group Co. Ltd. reported that its 2025 annual general meeting, along with separate class meetings for H shareholders and domestic shareholders, was held in Shanghai on 18 June 2026, with all board-attended resolutions passed by poll. Shar...
Sinopharm Sets 2025 AGM to Approve Dividend, Guarantees and Share Issuance Mandate
May 27, 2026
Sinopharm Group has called its 2025 annual general meeting for 18 June 2026 in Shanghai, where shareholders will review the board and supervisory committee reports, audited financial statements, and the proposed profit distribution and final divid...
Sinopharm Seeks Mandate to Repurchase Up to 10% of H Shares
May 27, 2026
Sinopharm Group has called an H shareholders’ class meeting in Shanghai on 18 June 2026 to seek approval for a special resolution granting its board a general mandate to repurchase up to 10% of the company’s H shares in issue, excludin...
Sinopharm Seeks Shareholder Mandate for Up to 10% H-Share Buyback
May 27, 2026
Sinopharm Group has convened a domestic shareholders’ class meeting for 18 June 2026 in Shanghai to seek approval for a special resolution granting its board a general mandate to repurchase up to 10% of the company’s H shares in issue,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.